HomeStock ScreenerBharat ImmunologicalsQuarterly Results

Bharat Immunologicals Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹-17 Cr
QMarch 2023
Quarterly Results

In 2026, Bharat Immunologicals (BIBCL) reported revenue ₹9 Cr and net profit ₹-18 Cr. View BIBCL yearly price range for the annual high/low range and current price position.

BIBCL Quarterly Results — Revenue, Profit & EPS Highlights

Bharat Immunologicals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Bharat Immunologicals screener.

  • Revenue of ₹47 Cr in March 2023 (+0.0% vs March 2023, -41.2% vs March 2022)
  • Net Profit of ₹-17 Cr in March 2023 (+0.0% vs March 2023, -88.9% vs March 2022)
  • EBITDA of ₹-16 Cr in March 2023 (+0.0% vs March 2023)
  • Operating Margin of -41.0% in March 2023 (+0.0pp vs March 2023)
  • Earnings Per Share of ₹-3.95 in March 2023 (+0.0% vs March 2023)

Bharat Immunologicals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

BIBCL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric 2026 March 2023 March 2022 March 2021 March 2020 QoQ YoY
Revenue (₹ Cr) 9 47 80 87 68 -80.9% -
Net Profit (₹ Cr) -18 -17 -9 -18 -10 - -
EBITDA (₹ Cr) -17 -16 -4 -19 -9 - -
EPS (₹) -4.20 -3.95 -2.03 1.10 -2.36 - -
Operating Margin (%) -13.0% -41.0% -6.0% -24.0% -16.0% - -

BIBCL Share Price Trend — 1-Year Movement Across Quarterly Results

Bharat Immunologicals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse BIBCL shareholder distribution to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin -36.2%
EBITDA Margin -34.0%
Operating Margin -41.0%
ROE (Annual) -19.3%

Balance Sheet Highlights

Total Assets ₹186 Cr
Total Equity ₹88 Cr
Current Assets ₹33 Cr
Current Liabilities ₹6 Cr

Cash Flow Analysis

Operating Cash Flow ₹11 Cr
Investing Cash Flow ₹1 Cr
Financing Cash Flow ₹-15 Cr
Net Cash Flow ₹-3 Cr

Current Market Data

Current Price ₹14.16
Exchange BSE
Last Updated Sep 18, 2026

BIBCL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Bharat Immunologicals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026
₹441,477.63 Cr 1837.3 15,018 2,710 -5.6% - 18.0% 162.6
Divis Laboratories
Mar 2026
₹247,469.81 Cr 9375.0 2,986 751 -5.0% - 25.2% 331.2
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4840.0 4,111 364 +27.7% +42.2% 8.9% 420.5
Zydus Life Science
Mar 2026
₹112,607.65 Cr 1160.0 7,569 1,341 -4.3% - 17.7% 91.7
Cipla
Mar 2026
₹109,705.39 Cr 1394.5 6,612 543 -9.3% - 8.2% 203.0
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores